Tenofovir diphosphate triethylamine is primarily used in the treatment of HIV and chronic hepatitis B infections. It functions as a nucleotide reverse transcriptase inhibitor, effectively blocking the replication of the virus by inhibiting the reverse transcriptase enzyme. This compound is a key active metabolite of tenofovir, which is commonly administered in prodrug forms such as tenofovir disoproxil fumarate. Its application is critical in antiretroviral therapy (ART) regimens, helping to reduce viral load and improve immune function in patients. Additionally, it is utilized in pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals. The triethylamine component aids in the stabilization and solubility of the compound, enhancing its pharmacokinetic properties for effective therapeutic use.